Haemonetics Corporation

Good day and welcome to the Hamanetics Third Quarter Fiscal 23 Conference Call and Webcast. At this time, all participants are in a listen-only mode. After the speaker's presentation, there'll be a question and answer session. Instructions will be given at that time. As a reminder, this call is being recorded. I would like to turn the call over to David Trink, Manager, Investor Relations. You may begin.

Good morning, everyone.

Thank you for joining us for Humanetics third quarter fiscal 23 conference call and webcast. I'm joined today by Chris Simon, our CEO, Roy Galvin, president of our Global Plasma and Blood Center businesses, and James Durecka, our CFO. This morning, we posted our third quarter and year-to-date fiscal 23 results to our investor relations website, along with updates to our fiscal 23 guidance and the analytical tables with the information that we will refer to on this call. Unless otherwise noted, all revenue growth rates we will discuss today are organic and exclude the impact of currency fluctuation, strategic exits of product lines, acquisitions, and divestitures. Additionally, to help investors understand Humanetics' ongoing business performance, we will refer to non-GAAP financial measures. These measures exclude certain charges and income items. For additional details about excluded items, comparisons with the same periods in fiscal 22, and reconciliations to our GAAP results, please refer to our third quarter and year-to-date fiscal 23 earnings release posted on our IR website. Our remarks today will also include forward-looking statements, and our actual results may differ materially from the anticipated results. Please refer to the Safe Harbor Statement in the earnings release and other filings with the SEC for a complete list of risk factors that may impact our results. Additionally, in order to protect customer confidentiality, we will not be able to discuss any customer-specific details except as disclosed previously. And now, I'd like to turn it over to Chris.